Stratatech, a Mallinckrodt Company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Stratatech, a Mallinckrodt Company sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Stratatech, a Mallinckrodt Company: 9 sponsored US clinical trials, none currently recruiting.

Stratatech, a Mallinckrodt Company sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Trauma-related Wound, with 2 trials.

Top-decile sponsor footprint

Stratatech, a Mallinckrodt Company ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 3

StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

NCT05517902
TERMINATED Phase 1

StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

NCT04765202
COMPLETED Phase 3

StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )

NCT04123548
TERMINATED Phase 1

Multiple Applications of ExpressGraft-C9T1 Skin Tissue as a Treatment for Diabetic Foot Ulcers

NCT04134143
COMPLETED Phase 1

ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers

NCT02657876
COMPLETED Phase 3

StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements

NCT03005106
TERMINATED Phase 2

StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects

NCT03005054
COMPLETED Phase 1

StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

NCT01437852
COMPLETED Phase 1

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

NCT00618839

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 3

Therapeutic Areas

Trauma-related Wound 2
Skin Wound 2
Burns 2
Burn, Thermal 1

How the Stratatech, a Mallinckrodt Company early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 6 completed (67%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Trauma-related Wound (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Stratatech, a Mallinckrodt Company: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Stratatech, a Mallinckrodt Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Stratatech, a Mallinckrodt Company4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Stratatech, a Mallinckrodt Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Stratatech, a Mallinckrodt Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stratatech, a Mallinckrodt Company page

9 registered trials is a research-attention snapshot, not an endorsement of Stratatech, a Mallinckrodt Company or any single study.

  • None of Stratatech, a Mallinckrodt Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Trauma-related Wound is the condition Stratatech, a Mallinckrodt Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Trauma-related Wound trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Stratatech, a Mallinckrodt Company pipeline card: 9 registered trials from official public datasets.Report a data error.